Table 1. Participant characteristics for the 1,819 individuals with inflammatory marker data and the weighted population, by self-reported diabetes.
| Characteristic | Self-Reported Diabetes | |||
|---|---|---|---|---|
| No | Yes | |||
| N (%) | Weighted, N (%) | N (%) | Weighted, N (%) | |
| Total | 1,694 | 54,781 | 120 | 3,332 |
| Sex | ||||
| Female | 777 (45.9) | 26,763 (48.9) | 34 (28.3) | 1,493 (44.8) |
| Male | 917 (54.1) | 28,018 (51.1) | 86 (71.7) | 1,839 (55.2) |
| Age Group (years) | ||||
| ≤59 | 320 (18.9) | 15,827 (28.9) | 14 (11.7) | 501 (15.0) |
| 60–64 | 511 (30.2) | 19,644 (35.9) | 31 (25.8) | 779 (23.4) |
| 65–69 | 505 (29.8) | 10,856 (19.8) | 40 (33.3) | 1,016 (30.5) |
| ≥70 | 358 (21.1) | 8,453 (15.4) | 35 (29.2) | 1,035 (31.1) |
| BMI Category (kg/m2) | ||||
| ≤25 | 616 (36.4) | 17,246 (31.5) | 22 (18.3) | 761 (22.9) |
| 25-<30 | 739 (43.6) | 25,657 (46.8) | 50 (41.7) | 1,207 (36.2) |
| ≥30 | 319 (18.8) | 11,034 (20.1) | 47 (39.2) | 1,363 (40.9) |
| Smoking Status | ||||
| Never | 517 (30.5) | 25,974 (47.4) | 30 (25.0) | 1,172 (35.2) |
| Former | 784 (46.3) | 23,457 (42.8) | 71 (59.2) | 1,922 (57.7) |
| Current | 393 (23.2) | 5,350 (9.8) | 19 (15.8) | 238 (7.1) |
| Original Case-Control Study | ||||
| Lung Cancer Study | 922 (54.4) | 23,477 (42.9) | 74 (61.7) | 931 (28.0) |
| Non-Hodgkin Lymphoma Study | 529 (31.2) | 22,282 (40.7) | 40 (33.3) | 1,978 (59.4) |
| Ovarian Cancer Study | 243 (14.3) | 9,021 (16.5) | 6 (5.0) | 422 (12.7) |
| Case-Control Statusa | ||||
| Case | 815 (48.1) | 645 (1.2) | 59 (49.2) | 54 (1.6) |
| Control | 879 (51.9) | 54,136 (98.8) | 61 (50.8) | 3,278 (98.4) |
After weighting, self-reported diabetes cases were older and had a higher body mass index than did people without a history of self-reported diabetes. Otherwise, participant characteristics were similar. Columns do not add to 100% due to missing data (individuals missing diabetes information, N = 5)
aCases were individuals without cancer at the time of blood collection, but who developed either lung, NHL, or ovarian cancer over the course of follow-up. Controls were free of cancer of interest of each study at the time of selection.